This Common Gut Bacteria Family Could Predict Liver Disease Survival

If a routine gut microbiome test flagged one bacterial family as unusually low, would it change how you think about liver health? A new review pulls together years of research on Lachnospiraceae, a group of gut bacteria that normally makes up between 10 and 45 percent of the bacteria in a healthy adult's stool, and finds its depletion shows up again and again across chronic liver disease, from cirrhosis to liver cancer. For anyone managing a liver condition, or just trying to understand what their gut has to do with it, the pattern is striking, even though it isn't a diagnostic tool yet.

Key Takeaways

• Lower levels of the gut bacteria family Lachnospiraceae consistently track worse liver disease, from cirrhosis severity to 30-day mortality risk in hospitalized patients.
• In one randomized trial, a fecal microbiota transplant (FMT) beat steroids on 90-day survival in alcohol-associated cirrhosis; in a separate liver cancer cohort, one Lachnospiraceae species tracked better response to immunotherapy.
• This is a review of existing studies, not new experiments, and most of the links it describes are correlations rather than proven cause and effect.

Lachnospiraceae Depletion Tracks Liver Disease Severity

Patients with chronic liver disease consistently have less Lachnospiraceae, a family of gut bacteria that includes well-studied genera like Roseburia and Coprococcus, and the shortfall gets worse as disease severity climbs. That's the throughline of a review published in the International Journal of Molecular Sciences, which pulled together a meta-analysis of 53 studies covering 5,076 participants. That pooled dataset found significantly lower Lachnospiraceae (and a related family, Ruminococcaceae) in cirrhosis patients versus healthy people, with lower levels tracking a worse Child-Pugh score, a standard scale doctors use to grade how advanced a patient's cirrhosis is.

Cirrhosis and Alcohol-Related Liver Disease Patients Have the Most at Stake

People hospitalized with advanced cirrhosis are the group where this pattern carries the highest stakes: in the same pooled data, reduced Lachnospiraceae abundance was independently associated with acute-on-chronic liver failure (ACLF, a sudden and life-threatening decompensation) and with elevated 30-day mortality. That fits with an earlier quantitative metagenomics study that linked gut microbiome depletion in cirrhosis to ACLF risk and prognosis. The review also describes multiple studies showing the same depletion pattern in alcohol-associated liver disease (ALD), using 16S rRNA sequencing (a genetic method for identifying which bacteria are present), suggesting a shared microbial thread runs through a disease spectrum that affects people with long drinking histories as well as those with metabolic risk factors for fatty liver.

This Is a Review Built on a Meta-Analysis, a Randomized Trial, and Cohort Data

The paper itself isn't a single new experiment. It's a narrative review, meaning the authors synthesized findings from other researchers' published studies rather than running their own trial. The strongest single piece of clinical evidence it cites is a randomized trial comparing FMT with steroids (prednisone) in patients with alcohol-associated cirrhosis, conducted by Bajaj and colleagues. The review also draws on a cohort of 113 patients with HBV-related hepatocellular carcinoma (HCC, the most common form of liver cancer), plus a range of smaller mechanistic and observational studies. That mix, a big pooled meta-analysis, one randomized trial, and several smaller cohorts, is the evidentiary backbone, and it's worth knowing which claims rest on which.

What the Findings Could Mean for Someone Living With Liver Disease

In the FMT trial, patients who received a fecal transplant showed better 90-day survival than those given prednisone, along with reduced alcohol cravings, improved cognition, and fewer serious adverse events over six months. Separately, in the HCC cohort, patients whose gut carried more of a specific species, Lachnospiraceae bacterium GAM79, tended to respond better to anti-PD-1 immunotherapy (a cancer treatment that unblocks the immune system) and lived significantly longer without disease progression, a pattern that echoes findings in a broader hepatobiliary cancer immunotherapy study. Neither result means a person should seek out a do-it-yourself fecal transplant or a Lachnospiraceae supplement; FMT for liver disease remains investigational, and gut bacteria testing isn't yet part of routine liver care. What it does mean is that a patient in an FMT or immunotherapy trial, or one asking a hepatologist about newer treatment options, now has a specific microbial thread worth asking about.

The Big Caveat: This Is a Review, Not a New Trial

The review synthesizes existing observational and trial data rather than presenting a single new study, and most of the disease associations it describes are correlational, meaning bacteria levels move together with disease severity without proof that low Lachnospiraceae directly causes worse outcomes. The FMT and immunotherapy-response links come from small, early-phase trials and cohorts, not confirmed large randomized controlled trials, so none of this should be read as an established treatment.

What Comes Next for Gut-Liver Research

Several mechanisms proposed in the review still need testing in people rather than mice. In an ALD mouse model, a Lachnospiraceae-derived metabolite called N-acetyl-glutamic acid activated a cellular stress-response pathway (KEAP1-NRF2) that suppressed a form of cell death called ferroptosis; in a MASLD (metabolic dysfunction-associated steatotic liver disease, the modern name for fatty liver disease) mouse model, an engineered strain of Coprococcus comes that secretes the immune signaling protein IL-22 improved glucose handling and reduced fatty liver buildup. The review also notes that antiviral therapy (entecavir) reversed microbial imbalance in hepatitis B patients, and that the antibiotic rifaximin suppressed Roseburia (a Lachnospiraceae genus) in patients with treatment-resistant ascites, hints that existing liver drugs already shift this bacterial family, intentionally or not, a point a review of gut microbial metabolite pathways also raises. Larger, prospective human trials are the logical next step before any of this becomes something a doctor tests for.

Common Questions

What exactly is Lachnospiraceae? It's a family of gut bacteria, including genera like Roseburia, Coprococcus, and Blautia, that typically makes up 10 to 45 percent of the bacteria in a healthy adult's stool and helps produce short-chain fatty acids and bile acid byproducts that support gut and liver function.

Can diet increase Lachnospiraceae levels? The review cites one dietary intervention using a plant-protein diet that produced an 8.06-fold increase in a specific subgroup, Lachnospiraceae UCG 006, alongside improvement in liver tissue samples, but this was a small intervention, not proof that diet change reverses liver disease on its own.

Does low Lachnospiraceae cause liver disease, or is it just a marker? The review can't establish causation; it's correlational data showing the two move together, though it proposes plausible mechanisms (short-chain fatty acid and bile acid signaling) for how the bacteria could influence liver inflammation.

Is fecal microbiota transplant an approved liver disease treatment now? No. The trial cited compared FMT with steroids in alcohol-associated cirrhosis and found better survival, but FMT for liver disease remains investigational and isn't standard care.

References

1. Jincheng Feng, Xueling Wang, Huan Cao, et al. (2026). The Role of Lachnospiraceae in Liver Diseases: Recent Advances and Clinical Application Prospects. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27167175